{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:50:43Z","timestamp":1791496243969,"version":"4.3.4"},"reference-count":74,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:p>Chronic hepatitis B (CHB) remains a major global public health problem. The functional cure is the ideal therapeutic target recommended by the latest guidelines, and pursuing a functional cure has become the key treatment end point of current therapy and for upcoming clinical trials. In this review, based on the latest published clinical research evidence, we analyzed the concept and connotation of clinical cures and elaborated on the benefits of clinical cures in detail. Secondly, we have summarized various potential treatment methods for achieving clinical cures, especially elaborating on the latest research progress of interferon\u2010based optimized treatment strategies in achieving clinical cures. We also analyzed which populations can achieve clinical cures and conducted a detailed analysis of relevant virological and serological markers in screening clinical cure advantage populations and predicting clinical cure achievement. In addition, we also introduced the difficulties that may be encountered in the current pursuit of achieving a clinical cure.<\/jats:p>","DOI":"10.1002\/cpt.3287","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T12:19:20Z","timestamp":1714479560000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Optimal Treatment Based on Interferon No Longer Makes Clinical Cure of Chronic Hepatitis B Far Away: An Evidence\u2010Based Review on Emerging Clinical Data"],"prefix":"10.1002","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1221-1327","authenticated-orcid":false,"given":"Yujing","family":"Li","sequence":"first","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2709-6076","authenticated-orcid":false,"given":"Fada","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6008-155X","authenticated-orcid":false,"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4702-6219","authenticated-orcid":false,"given":"Lanqing","family":"Li","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-4600","authenticated-orcid":false,"given":"Chengrun","family":"Song","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8523-1689","authenticated-orcid":false,"given":"Enqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Center of Infectious Diseases, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"e_1_2_9_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.01.003"},{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2020-002306"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.18.219469"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1159\/000080872"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037198"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240375"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.04.018"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.08.010"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2007.02.021"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i23.7152"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14020434"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbac030"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2021.0112"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i2.401"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312653"},{"key":"e_1_2_9_16_1","article-title":"Long\u2010term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B","volume":"8","author":"Roade L.","year":"2021","journal-title":"Therapeutic Adv Infect Dis"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12096"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13126"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.05.041"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010213"},{"key":"e_1_2_9_21_1","first-page":"594","article-title":"The expert consensus on clinical cure (functional cure) of chronic hepatitis B","volume":"27","author":"Chinese Society of Infectious Disease Chinese Society Of Hepatology, Chinese Medical Association","year":"2019","journal-title":"Chin J Hepatol"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16659"},{"key":"e_1_2_9_23_1","first-page":"881","article-title":"The guidelines of prevention and treatment for chronic hepatitis B","volume":"13","author":"Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases","year":"2005","journal-title":"Chinese J Hepatol"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105782"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322571"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034968"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21187"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba6322"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005788"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab216"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv180"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43078-5"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733364"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2016.06.002"},{"key":"e_1_2_9_36_1","first-page":"255","article-title":"Pegylated interferon alpha\u20102a (40 kDa) in the treatment of chronic hepatitis B","volume":"1","author":"Lai L.","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328362389a"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.01.006"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.031"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17701-0"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv547"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.044"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2017.00072"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)32161-9"},{"key":"e_1_2_9_45_1","article-title":"Effectiveness of response\u2010guided Peginterferon Alfa\u20102a therapy in Nucleos(t)ide analogues treated patients with HbeAg\u2010positive chronic hepatitis B: interim analysis of a prospective, multi\u2010center, randomized study","author":"Xie Q.","year":"2018","journal-title":"Hepatology"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230893"},{"key":"e_1_2_9_47_1","article-title":"Functional cure based on pegylated interferon \u0251\u20102b therapy in nucleoside analog\u2010suppressed HBeAg negative chronic hepatitis B: a multi\u2010center real\u2010world study (Everest project in China)\u20104\u2009years data update","author":"Mo Z.","year":"2022","journal-title":"AASLD"},{"key":"e_1_2_9_48_1","unstructured":"Zhang Q.R.et al.The functional cure strategies of patients with high HBsAg levels at baseline with interferon therapy (OASIS Project 1.5 Year Data). APASL2023 Abstracts (FP13\u201070)."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2022.2074977"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210027"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.02.058"},{"key":"e_1_2_9_52_1","first-page":"129","article-title":"Viral hepatitis. HBV cure \u2013 can we pin our hopes on immunotherapy?","volume":"12","author":"Yang H\u2010C","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_9_53_1","unstructured":"Kennedy P.T.et al.Efficacy and safety of siRNA JNJ\u201073763989 capsid assembly modulator\u2010E (CAM\u2010E) JNJ\u201056136379 and nucleos(t)ide analogs (NA) with pegylated interferon alpha\u20102a (PegIFN\u03b12a) added in immune\u2010tolerant patients with chronic hepatitis B virus (HBV) infection: interim results from the phase 2 REEF\u2010IT study. AASLD2023 Abstract (1468\u2010C)."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3890309"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)01971-7"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i11.1076"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12691"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.04.031"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13471"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01303-18"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.003"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0032"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.039"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.01.021"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29213"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.029"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891424"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-409"},{"key":"e_1_2_9_69_1","first-page":"1059","article-title":"Soluble CD163 and CD163 expression on monocytes associated with chronic hepatitis B inflammation and HBsAg loss","volume":"10","author":"Xie P.","year":"2022","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15489"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.04.020"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.018"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13634"},{"key":"e_1_2_9_74_1","doi-asserted-by":"crossref","unstructured":"Gielen V.et al.Hepatitis B surface antigen loss rate and safety and discontinuations with pegylated interferon alpha in chronic hepatitis B virus infection a systematic review. EASL2023. Abstract (SAT\u2010164).","DOI":"10.1016\/S0168-8278(23)03277-4"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T08:12:59Z","timestamp":1727511179000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1002\/cpt.3287"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3287","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"assertion":[{"value":"2024-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}